LGND - Ligand Pharmaceuticals Incorporated
| Previous Close | 104.22 |
| Open | 104.30 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1000 |
| Day's Range | 103.17 - 107.41 |
| 52 Week Range | 84.45 - 149.05 |
| Volume | 223,094 |
| Avg. Volume | 377,725 |
| Market Cap | 1.9B |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | 3.78 |
| EPS (TTM) | 28.29 |
| Earnings Date | Feb 5, 2020 - Feb 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2010-07-02 |
| 1y Target Est | 196.20 |
- Benzinga
12 Biotech Stocks Primed For A Short Squeeze
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
- Zacks
Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi
Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi. Under the agreement, Sanofi will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™ in addition to Ligand’s patented antigen technology. OmniAb is licensed to over 40 corporate partners globally, and this deal with Sanofi adds to a growing portfolio of OmniAb discovery and clinical development programs with global fully-integrated pharmaceutical companies.
- Thomson Reuters StreetEvents
Edited Transcript of LGND earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Ligand Pharmaceuticals Inc Earnings Call
- Business Wire
Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
Ligand Pharmaceuticals Incorporated (LGND) today announced it ranked in Deloitte’s Technology Fast 500™, a listing of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 25th year. “This is the third time Ligand has been included in the Technology Fast 500, and we are very pleased once again to be recognized by Deloitte for our rapid revenue growth,” said John Higgins, Chief Executive Officer of Ligand.
- Business Wire
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Presentation at the American Society of Nephrology Kidney Week 2019
- Business Wire
Ligand to Participate in the Stephens 2019 Nashville Investment Conference
Ligand Pharmaceuticals Incorporated (LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. Matt Korenberg, CFO will attend for Ligand. Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
- Zacks
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
CNW GroupTalem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals
VICTORIA , Nov. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, a wholly-owned subsidiary, has entered into a worldwide OmniAb® platform license agreement with Ligand Pharmaceuticals (LGND). This license enables Talem to access Ligand's unique OmniAb platform for use with Talem's leading antibody discovery capabilities. Under the license, Talem has the right to develop and partner fully human antibodies in OmniRat®, OmniFlic®, OmniMouse®, OmniChicken®, and OmniClic™.
- Business Wire
Ligand Reports Third Quarter 2019 Financial Results
Conference Call Begins at 4:30 p.m. Eastern Time Today
- Zacks
Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Is Ligand Pharmaceuticals Inc. (LGND) Going To Burn These Hedge Funds ?
Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]
- Business Wire
Ligand to Report Third Quarter 2019 Results on November 5th
Ligand Pharmaceuticals Incorporated announced today plans to report third quarter 2019 financial results on November 5, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
- Business Wire
Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
Ligand Pharmaceuticals Incorporated (LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a privately held biotechnology company pioneering the use of antibody-oligonucleotide conjugates (AOC™) to treat rare muscle disorders and other serious diseases. Ms. Boyce's appointment increases the number of Ligand directors to nine.
- Simply Wall St.
Who Has Been Buying Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- CNW Group
ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom
VICTORIA , Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Brian Lundstrom to the company's Board of Directors. Trained in immunology and international business, Mr. Lundstrom has over 30 years' experience from mostly publicly traded companies with a focus on antibody therapeutics.
- GlobeNewswire
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the first patient into a Phase 2 clinical trial of its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE, NCT03781063) study will assess the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint.
- Zacks
Ligand (LGND) Surges: Stock Moves 6.3% Higher
Ligand (LGND) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks
Why Is Ligand (LGND) Down 0.9% Since Last Earnings Report?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Retrophin Down on Neurological Disorder Drug Study Failure
Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.
- Motley Fool
3 Top Biotech Stocks to Buy in August
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
- Thomson Reuters StreetEvents
Edited Transcript of LGND earnings conference call or presentation 30-Jul-19 1:00pm GMT
Q2 2019 Ligand Pharmaceuticals Inc Earnings Call
